Alcon and AAM Launch Systane® Complete, Indonesia’s First Lipid-Based Solution for Dry Eye Disease

Dry eye disease is among the most commonly reported ocular health conditions today, with symptoms ranging from dryness and irritation to blurred vision, all of which can significantly affect daily comfort and quality of life.

A retrospective study involving 159 dry eye patients conducted by Lemp MA and colleagues and published in Cornea revealed that approximately 50% of patients suffer from Evaporative Dry Eye, 36% from Mixed Dry Eye, and 14% from Aqueous Deficient Dry Eye. These findings indicate that the majority of dry eye patients require a therapeutic approach that not only replenishes moisture but also supports overall tear film stability.

This condition is particularly relevant in Asia, where the prevalence of Meibomian Gland Dysfunction (MGD)—one of the primary causes of evaporative dry eye—is reported to be higher than in other regions, ranging from 46% to 70%. Environmental factors such as temperature, humidity levels, and air quality further contribute to the high incidence of dry eye disease in the region.

“Based on the studies we have conducted, dry eye symptoms are currently experienced by approximately three out of four patients who seek consultation with eye care professionals. Building on these findings, we developed this product to help medical professionals manage a broad range of dry eye symptoms more comprehensively,” said Patcharin Charmnoot, Alcon SEA Cluster Head.

Building on these insights, PT Anugrah Argon Medica (AAM), a subsidiary of PT Medela Potentia Tbk (MDLA), in collaboration with Alcon, officially launched Systane® Complete Multi-Dose Preservative-Free, Alcon’s innovative eye drop designed as a comprehensive solution for the full spectrum of dry eye disease—the first of its kind in Indonesia—on Sunday, 1 February 2026, at The Ritz-Carlton Jakarta.

The launch event was attended by the President Director of PT Medela Potentia Tbk, Krestijanto Pandji; President Director of PT Anugrah Argon Medica, Juliwaty; Commercial Director of AAM Budi Lim; Alcon SEA Cluster Head Patcharin Charmnoot; Chairperson of the Indonesian Ocular Infection & Immunology Society (INOIIS) PERDAMI Prof. Dr. dr. Ratna Sitompul, Sp.M(K), and Chairperson of PERDAMI Jaya dr. Julie Dewi Barliana, Sp.M(K), M.Biomed. The event was also attended by approximately 100 ophthalmologists, particularly cornea and dry eye subspecialists, from leading hospitals and eye clinics across Indonesia.

The launch was accompanied by a scientific symposium titled “Complete Lipid Layer Restoration,” featuring three sessions: Lipid Layer Deficiency and Tear Evaporation: Rethinking the Pathophysiology of MGD-Related Dry Eye by dr. Rifna Luftiamida, Sp.M(K); The Role of Topical Combination of Hydroxypropyl Guar (HP-Guar) and Nano-Sized Lipid Droplets in Lipid Layer Changes of Dry Eye Diseases by dr. Yulia Aziza, Sp.M(K), PhD; and Complete Lipid Layer Restoration: Hands-On Clinical Experience Using HP-Guar and Nano-Sized Lipid Droplet Technology by Dr. Nina Asrini Noor, Sp.M.

The launch of Systane® Complete Multi-Dose Preservative-Free marks a strategic collaboration between Alcon, AAM, and INOIIS PERDAMI, amid the absence of mineral oil-based artificial tears in Indonesia that are specifically indicated for the treatment of evaporative dry eye caused by MGD.

“At this moment, we are proud to introduce Systane® Complete Multi-Dose Preservative-Free as a preservative-free, multi-dose formulation. We hope this product will become a valuable treatment option in supporting dry eye management, particularly for patients with evaporative dry eye and MGD,” said Juliwaty, President Director of PT Anugrah Argon Medica.

MGD is a condition in which the function of the meibomian glands is impaired, resulting in suboptimal formation of the lipid layer of the tear film. As a consequence, tear evaporation accelerates, leading to various dry eye symptoms.

Responding to this development, Prof. Dr. dr. Ratna Sitompul, Sp.M(K) emphasized the importance of eye drop therapies that support MGD management as a significant advancement in clinical practice in Indonesia.

“Today, we are witnessing new convenience in the management of MGD through eye drop therapy. This presents a valuable opportunity for medical professionals to deliver more targeted treatment in accordance with patients’ needs,” she said.

Systane® Complete Multi-Dose Preservative-Free is indicated for the full spectrum of dry eye disease, including evaporative dry eye caused by lipid layer disruption, aqueous-deficient dry eye resulting from insufficient aqueous layer, and mixed dry eye. The product works by supporting all layers of the tear film, including the lipid layer, thereby helping to maintain tear film stability and relieve dry eye symptoms comprehensively.

The product features nano-sized lipid droplet technology combined with Hydroxypropyl Guar (HP-Guar), which has been clinically proven to provide multi-symptom relief for dry eye patients. In addition, Systane® Complete Multi-Dose Preservative-Free utilizes PureFlow® Technology, a preservative-free multi-dose bottle with a one-way valve designed to prevent contamination and enhance ease of use—the first in Indonesia.

“With the technology incorporated in Systane® Complete Multi-Dose Preservative-Free, a single drop can spread more optimally across the ocular surface. Moreover, the preservative-free multi-dose formulation is expected to support both medical professionals and patients in managing dry eye disease more effectively,” concluded Patcharin Charmnoot.